A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

Table 4 Best overall response as per investigator review (FAS − expansion phase)

	Alpelisib 350 mg + Imatinib (N = 35)	95% CI
Best overall response, n (%)
CR	0
PR	1 (2.9)
SD	15 (42.9)
Progressive disease	14 (40.0)
Unknown^a	5 (14.3)
Clinical benefit rate (CBR: CR + PR + SD ≥ 16 weeks)	9 (25.7)	(12.5, 43.3)
Overall response rate (ORR: CR + PR)	1 (2.9)	(0.1, 14.9)
Disease control rate (DCR: CR + PR + SD > 6 weeks)	16 (45.7)	(28.8, 63.4)

^aUnknown refers to the patients whose post-baseline assessments were not available due to premature treatment discontinuation
CBR clinical benefit rate, CI confidence interval, CR complete response, DCR disease control rate, FAS full analysis set, ORR overall response rate, PR partial response, SD stable disease

ISSN: 1471-2407